Safety and Effectiveness of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan: A Post-Marketing Surveillance Study
Canakinumab showed a favourable long-term safety profile and sustained effectiveness in Japanese patients with sJIA inadequately controlled by existing therapies. No new safety concerns emerged, and the safety profile was comparable to that observed in the earlier phase III study.
Authors
- Noriko Seko
- Tomohiro Yoneda
- Fumio Akita
Institutions
- Novartis (Japan) (JP)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1007/s40744-025-00822-1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharma